Biogen (BIIB) PT Raised to $408 at Cowen
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $216.03 +6.97%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Join SI Premium – FREE
Cowen raised its price target on Biogen (NASDAQ: BIIB) to $408.00 (from $338.00) while maintaining an Outperform rating.
Analyst Eric Schmidt highlighted that the MS franchise is steady while Spinraza sales were strong as the drug's ex-U.S. launch has accelerated.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Starts TIME dotCom Berhad (TDC:MK) at Overweight
- Lenovo Group Ltd. (992:HK) (LNVGY) PT Raised to HK$31 at Citi
- Shenzhou International Group Holdings Ltd (2313:HK) (SHZHY) PT Lowered to HK$50 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
